Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
79.02 USD | +0.87% | +6.05% | -7.96% |
Business Summary
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Number of employees : 17,000
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Innovative Medicines
100.0
%
| 27,305 | 100.0 % | 27,281 | 100.0 % | -0.09% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
69.2
%
| 19,267 | 70.6 % | 18,884 | 69.2 % | -1.99% |
Europe
16.4
%
| 4,874 | 17.9 % | 4,469 | 16.4 % | -8.31% |
Other International
14.4
%
| 3,164 | 11.6 % | 3,928 | 14.4 % | +24.15% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 58 | 2019 |
Andrew Dickinson
DFI | Director of Finance/CFO | 53 | 2015 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 2021 |
Merdad Parsey
CTO | Chief Tech/Sci/R&D Officer | 60 | 2019 |
Jacquie Ross
IRC | Investor Relations Contact | - | 2020 |
Janet Dorling
PRN | Corporate Officer/Principal | 49 | 2020 |
Adam Levy
PRN | Corporate Officer/Principal | - | - |
Stacey Ma
PRN | Corporate Officer/Principal | 53 | 2022 |
Mark Genovese
PRN | Corporate Officer/Principal | - | 2020 |
Tomas Cihlar
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Anthony Welters
BRD | Director/Board Member | 68 | 2020 |
Director/Board Member | 70 | 2017 | |
Kevin Lofton
BRD | Director/Board Member | 68 | 2009 |
Director/Board Member | 69 | 2018 | |
Javier Rodriguez
BRD | Director/Board Member | 52 | 2020 |
Daniel O'Day
CEO | Chief Executive Officer | 58 | 2019 |
Sandra Horning
BRD | Director/Board Member | 74 | 2020 |
Kelly Kramer
BRD | Director/Board Member | 55 | 2016 |
Director/Board Member | 69 | 2020 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 1,246,041,895 | 1,244,607,836 ( 99.88 %) | 0 | 99.88 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
GALAPAGOS NV 25.35% | 16,707,477 | 25.35% | 551,515,654 $ |
ASSEMBLY BIOSCIENCES, INC. 24.84% | 13,073,668 | 24.84% | 11,465,607 $ |
ARCUS BIOSCIENCES, INC. 19.90% | 14,823,029 | 19.90% | 232,869,786 $ |
ALLOVIR, INC. 14.61% | 16,635,286 | 14.61% | 24,952,929 $ |
ARCELLX, INC. 7.19% | 3,478,261 | 7.19% | 122,608,700 $ |
IKENA ONCOLOGY, INC. 6.69% | 2,931,467 | 6.69% | 11,813,812 $ |
TANGO THERAPEUTICS, INC. 4.77% | 4,854,443 | 4.77% | 40,777,321 $ |
HOOKIPA PHARMA INC. 4.61% | 3,759,465 | 4.61% | 1,624,089 $ |
Company contact information

Group companies
Name | Category and Sector |
---|---|
Gilead Sciences Ireland UC
|
-
|
Gilead Therapeutics A1 Unlimited Co.
|
Health Technology - Pharmaceuticals: Major
|
Sector
Sales per region
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
79.02USD
Average target price
90.39USD
Spread / Average Target
+14.39%
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.96% | 97 615 M $ | |
+60.77% | 527 B $ | |
+46.50% | 448 B $ | |
-10.25% | 382 B $ | |
-4.25% | 266 B $ | |
-10.54% | 255 B $ | |
-13.61% | 227 B $ | |
+1.76% | 203 B $ | |
-9.57% | 201 B $ | |
-43.23% | 165 B $ |
- Stock
- Equities
- Stock Gilead Sciences, Inc. - Nasdaq
- Company Gilead Sciences, Inc.